Press Coverage

The one-trial era: what the FDA’s shift signals for the future of drug development

The FDA is shifting toward approving drugs based on a single pivotal trial supported by…

CertaraMay 6, 2026

Blog

How Pharma Can Transition to Non-animal Studies for Investigational Drugs

Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…

CertaraMay 5, 2026

Blog

From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development

Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…

CertaraApril 28, 2026

Blog

Top 10 Benefits of Simcyp® Simulator for Drug Development

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= April 23, 2026 Physiologically based pharmacokinetic (PBPK) modeling has evolved from an emerging methodology…

CertaraApril 23, 2026

On-Demand Webinar

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Watch this on-demand webinar to learn how the final ICH M15 guidance is shaping Model-Informed…

CertaraApril 2, 2026

On-Demand Webinar

Leveraging the full potential of PBPK models to accelerate drug development

Explore how Novartis applies PBPK modeling in drug development using Simcyp to support regulatory decisions,…

CertaraMarch 20, 2026

Blog

What are Common Bioequivalence Study Mistakes?

Learn about the most common bioequivalence study mistakes drug developers make and the differences between…

CertaraMarch 20, 2026

Blog

ICH M15 Guideline: What the Finalized Guideline Means for Model-Informed Drug Development

With the release of the draft ICH M15 guidance, MIDD is no longer optional -…

CertaraMarch 18, 2026

Conference

Discovery & Development Europe 2026

CertaraMarch 13, 2026

Announcement

Certara Expands Simcyp® Simulator to Streamline Regulatory Submissions and Internal Efficiencies

Discover how the Simcyp Simulator’s PBPK models can streamlines drug development and reduces the number…

CertaraMarch 5, 2026

Certara Products – Simcyp

The one-trial era: what the FDA’s shift signals for the future of drug development

How Pharma Can Transition to Non-animal Studies for Investigational Drugs

From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development

Top 10 Benefits of Simcyp® Simulator for Drug Development

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Leveraging the full potential of PBPK models to accelerate drug development

What are Common Bioequivalence Study Mistakes?

ICH M15 Guideline: What the Finalized Guideline Means for Model-Informed Drug Development

Discovery & Development Europe 2026

Certara Expands Simcyp® Simulator to Streamline Regulatory Submissions and Internal Efficiencies

Newsletter sign up

Quick links

Solutions

Contact